UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 10, 2005
GENENTECH, INC.
|
Delaware of incorporation) |
1-9813 File Number) |
94-2347624 Identification No.) |
1 DNA Way
South San Francisco, California 94080-4990
(Address of principal executive offices and Zip Code)
Registrant's telephone number, including area code: (650) 225-1000
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
[ ] |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
[ ] |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
[ ] |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
[ ] |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
|
ITEM 2.02. |
RESULTS OF OPERATIONS AND FINANCIAL CONDITION |
On October 10, 2005, Genentech, Inc., a Delaware corporation, issued a press release announcing earnings for the quarter ended September 30, 2005. A copy of the earnings press release is furnished as Exhibit 99.1 to this report.
The attached press release contains both GAAP and non-GAAP financial measures. The non-GAAP financial measures included are net income and earnings per share (or EPS). These non-GAAP financial measures exclude recurring charges related to the redemption of our callable putable common stock on June 30, 1999 (the "Redemption") and litigation-related special items, and their related tax effects. Non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures prepared in accordance with GAAP.
The press release includes non-GAAP financial measures because our management uses this information to monitor and evaluate Genentech's operating results and trends on an on-going basis. Our management believes the non-GAAP information is also useful for investors because the amounts relating to the Redemption and push-down accounting and the litigation-related special items that are excluded were the result of transactions that are unusual due to their nature, size or infrequency. Consequently, excluding those items from our operating results provides users of the financial statements an important insight into our operating results and related trends that affect our business. In addition, our management uses non-GAAP financial information and measures internally for operating, budgeting and financial planning purposes.
|
ITEM 8.01. |
OTHER EVENTS |
A copy of our consolidated statements of income data for the three and nine months ended September 30, 2005, and consolidated balance sheets data at September 30, 2005 prepared in accordance with GAAP is filed as Exhibit 99.2 to this report.
|
ITEM 9.01. |
FINANCIAL STATEMENTS AND EXHIBITS |
|
(c) |
Exhibits. |
|
Exhibit No. |
||
|
99.1 |
Earnings Press Release of Genentech, Inc. dated October 10, 2005. |
|
|
99.2 |
Consolidated Statements of Income and Balance Sheets Data |
|
- 2 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
GENENTECH, INC.
|
|||
|
Date: |
October 10, 2005 |
/s/ARTHUR D. LEVINSON |
|
|
Arthur D. Levinson, Ph.D. |
|||
|
Date: |
October 10, 2005 |
/s/DAVID A. EBERSMAN |
|
|
David A. Ebersman |
|||
|
Date: |
October 10, 2005 |
/s/JOHN M. WHITING |
|
|
John M. Whiting |
- 3 -
EXHIBIT INDEX
|
Exhibit No. |
Description |
|
|
99.1 |
Earnings Press Release of Genentech, Inc. dated October 10, 2005. |
|
|
99.2 |
Consolidated Statements of Income and Balance Sheets Data |
|
- 4 -